Diabetes Amputation Risk Not Worsened by SGLT-2 InhibitorsByPatrick Campbell & Kevin KunzmannMarch 17th 2019A 3 million-plus patient longitudinal study found the drug class was no worse for amputation risks than other diabetes therapies, despite recent conflicting studies.